Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Considers Mapping Generic Drug Complaints To Spot Safety Trends

Executive Summary

A cluster of complaints in one area may inform a new safety signal or other problem, agency official says.

Advertisement

Related Content

Checkpoint Inhibitors: US FDA Wants Consistent Adverse Event Definitions
US FDA Sets Generic Approval Record, But Generic Sponsors Aren't Celebrating
New CDER No. 2 May Impact FDA's Safety Monitoring Aspirations
FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution

Topics

Advertisement
UsernamePublicRestriction

Register

PS124674

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel